Deal to progress Alzheimer's vaccine

AFFiRiS GmbH has granted GlaxoSmithKline Biologicals S.A. (GSK) exclusive rights to develop and commercialise its Alzheimer's disease vaccine candidates. Two are currently in Phase I clinical development, and others are in preclinical development.

The AFFiRiS AFFiTOPE technology allows the design of proteins with very specific binding characteristics that are ideally suited for the development of vaccines against disease-causing ‘rogue’ human proteins, such as beta-amyloid – central to Alzheimer’s disease pathology.
AFFiRiS GmbH (www.affiris.com) develops peptide-based vaccines to combat Alzheimer’s disease, atherosclerosis and other diseases. The company has established platform technologies and a worldwide patent portfolio covering their vaccine candidates.

20.11.2008

News • Acute myeloid leukaemia

Six-gene scoring system could help predict AML survival

Acute myeloid leukaemia (AML) has widely variable outcomes from one patient to the next. Now, researchers, have created a new scoring system based on the activity of six different genes to help…

Taipei Brings Six Biomedical Innovations to MEDICA 2026

Six Taipei-based biomedical companies will showcase innovations in precision medicine and smart healthcare at MEDICA 2026 (November 16–19, Düsseldorf).

News • Trial investigates combined benefits

Liquid biopsy and mammography: a perfect match for breast cancer detection?

Could a liquid biopsy blood test help detect breast cancer earlier than a mammogram alone? A new clinical trial to evaluate this question has just started.